Boston Scientific (NYSE:BSX) Shares Gap Down – What’s Next?

Boston Scientific Corporation (NYSE:BSX)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $93.74, but opened at $88.26. Boston Scientific shares last traded at $89.3880, with a volume of 4,560,603 shares traded.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands BSX’s cardiovascular and neurovascular footprint, giving scaled entry into mechanical thrombectomy and faster growth adjacencies that could boost long‑term revenue and margins. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Recent smaller deals and regulatory wins (e.g., Valencia Technologies buy to add the eCoin ITNS device and FDA/CE approvals for electrophysiology products) provide additional, nearer‑term growth catalysts and product leverage. BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies
• Neutral Sentiment: Company release and analyst materials frame the deal as both strategic and accretive over time; management held a conference call to provide transaction details and integration plans. M&A Call – Slideshow
• Neutral Sentiment: Penumbra reported strong Q4 performance that supports a higher multiple and the strategic rationale for the deal; Penumbra shares rose on the news. Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy
• Negative Sentiment: Market reaction shows concern about the deal size, potential near‑term EPS dilution and share issuance — investors drove BSX shares lower after the announcement. Boston Scientific to acquire Penumbra in $14.5B deal
• Negative Sentiment: Potential legal/transactional risks: a shareholder investigation notice for Penumbra was announced, and large M&A deals carry integration and regulatory risks that could delay synergies or increase costs. BRODSKY & SMITH SHAREHOLDER UPDATE

Analysts Set New Price Targets

A number of research analysts recently issued reports on BSX shares. Leerink Partners lifted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Citigroup reiterated a “buy” rating on shares of Boston Scientific in a research note on Wednesday. Royal Bank Of Canada raised their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $125.21.

Boston Scientific Stock Performance

The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a 50-day simple moving average of $97.32 and a 200 day simple moving average of $100.53. The company has a market cap of $132.57 billion, a price-to-earnings ratio of 47.86, a price-to-earnings-growth ratio of 1.67 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 93,095 shares of company stock valued at $9,305,450 over the last quarter. 0.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Steph & Co. purchased a new stake in Boston Scientific in the 3rd quarter valued at approximately $25,000. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter worth $26,000. Finally, Sound Income Strategies LLC lifted its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.